BioCardia, Inc.

NasdaqCM:BCDA Voorraadrapport

Marktkapitalisatie: US$8.4m

BioCardia Inkomsten in het verleden

Verleden criteriumcontroles 0/6

BioCardia has been growing earnings at an average annual rate of 7.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9.8% per year.

Belangrijke informatie

7.8%

Groei van de winst

41.4%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei9.8%
Rendement op eigen vermogenn/a
Nettomarge-1,999.8%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

May 14
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Aug 24
Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

May 10
Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Jan 06
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Sep 23
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Opbrengsten en kosten

Hoe BioCardia geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:BCDA Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-940
31 Mar 240-1040
31 Dec 230-1240
30 Sep 231-1340
30 Jun 230-1340
31 Mar 231-1240
31 Dec 221-1240
30 Sep 221-1250
30 Jun 222-1250
31 Mar 221-1350
31 Dec 211-1350
30 Sep 211-1250
30 Jun 210-1350
31 Mar 210-1350
31 Dec 200-1560
30 Sep 200-1660
30 Jun 200-1560
31 Mar 201-1660
31 Dec 191-1560
30 Sep 191-1560
30 Jun 190-1560
31 Mar 191-1460
31 Dec 181-1460
30 Sep 181-1460
30 Jun 181-1360
31 Mar 181-1360
31 Dec 170-1260
30 Sep 171-1260
30 Jun 171-1360
31 Mar 171-1250
31 Dec 161-1040
30 Sep 161-730
30 Jun 161-730
31 Mar 161-630
31 Dec 151-740
31 Mar 151-1050
31 Dec 141-1040
31 Dec 132-630

Kwaliteitswinsten: BCDA is currently unprofitable.

Groeiende winstmarge: BCDA is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: BCDA is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Versnelling van de groei: Unable to compare BCDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: BCDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: BCDA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden